Peter Hecht, Cyclerion Therapeutics CEO
April 3, 2023 11:03 AM EDTUpdated 11:21 AM
Deals

Sec­ond time’s the charm? Cy­cle­ri­on CEO tries again at buy­ing biotech's as­sets

Kyle LaHucik

Senior Reporter

As the re­serves run dry, Cy­cle­ri­on Ther­a­peu­tics is look­ing for a way to keep its drug de­vel­op­ment am­bi­tions alive, and the biotech’s board is giv­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

As blue­bird projects more com­mer­cial de­mand, the biotech con­tin­ues to seek cash

Zai Lab aims to raise $200M; Kro­nos Bio to seek ‘strate­gic’ op­tions

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times